The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final molecular subgroups analyses.
 
Fotios Loupakis
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; Roche Pharma AG; Sanofi
Travel, Accommodations, Expenses - Amgen; Bayer; Roche Pharma AG; Sanofi
 
Chiara Cremolini
No Relationships to Disclose
 
Carlotta Antoniotti
No Relationships to Disclose
 
Sara Lonardi
Consulting or Advisory Role - Bayer
Speakers' Bureau - Roche
Research Funding - Sanofi
 
Monica Ronzoni
No Relationships to Disclose
 
Alberto Zaniboni
No Relationships to Disclose
 
Giuseppe Tonini
No Relationships to Disclose
 
Lisa Salvatore
No Relationships to Disclose
 
Silvana Chiara
No Relationships to Disclose
 
Chiara Carlomagno
No Relationships to Disclose
 
Chiara Banzi
No Relationships to Disclose
 
Francesca Negri
No Relationships to Disclose
 
Lorenzo Marcucci
No Relationships to Disclose
 
Carlo Barone
No Relationships to Disclose
 
Gabriella Fontanini
No Relationships to Disclose
 
Nicla Borrelli
No Relationships to Disclose
 
Mirella Giordano
No Relationships to Disclose
 
Elisabetta Macerola
No Relationships to Disclose
 
Luca Boni
Research Funding - AMGEN (Inst)
Patents, Royalties, Other Intellectual Property - International Patent nr. PCT/EP2012/065661
 
Alfredo Falcone
No Relationships to Disclose